May 10th 2024
Those with metastatic castration-resistant prostate cancer in the BRCA subgroup experienced worse outcomes vs those in non-BRCA subgroups, according to the results of the CAPTURE trial.
February 3rd 2024
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Adjuvant Nivolumab Falls Short of Disease-Free Survival End Point in Locally Advanced High-Risk RCC
January 27th 2024In the phase 3 CheckMate 914 trial, the use of nivolumab did not meet the primary endpoint of disease-free survival when compared to a placebo in patients with localized renal cell carcinoma at a heightened risk of relapse following nephrectomy.
Read More
Significance of Early Genetic Testing in HRR-Mutated mCRPC Highlighted by Real-World Observations
January 26th 2024Individuals diagnosed with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC) receiving olaparib face a critical requirement for timely and consistent genetic testing to enhance treatment outcomes.
Read More
Enhanced Progression-Free Survival: Cabozantinib Combination Outperforms NHT in Metastatic CRPC
January 25th 2024Research suggests that combining cabozantinib with atezolizumab could emerge as a promising alternative for individuals facing metastatic castration-resistant prostate cancer that has advanced after novel hormonal therapy.
Read More
Abiraterone, Prednisone, Apalutamide Improves Prostate Cancer Outcomes, Leaves HRQoL Unaffected
January 25th 2024Oncological outcomes improved with the addition of abiraterone acetate (Zytiga) plus prednisone (AAP) and apalutamide (Erleada) after radical prostatectomy and did not significantly affect health-related quality of life.
Read More
HRRm Tester Underutilized for mCRPC in the Real-World Setting
January 25th 2024While germline and somatic testing is standard of care in the metastatic castration-resistant prostate cancer setting, it is still underutilized in the real world, leading to negative impacts on therapeutic offerings.
Read More
Adding Darolutamide to ADT May Reduce Hospitalizations But Longer Stays in mHSPC
January 25th 2024Patients with metastatic hormone-sensitive prostate cancer treated with darolutamide plus androgen deprivation therapy and docetaxel had lower rates of hospitalizations but marginally longer lengths of stay compared with those treated with placebo, androgen deprivation therapy, and docetaxel.
Read More
Wave of Innovation Reshapes Treatments for Genitourinary Cancers
January 18th 2024Francesca Jackson-Spence, PhD, and Matthew Young, MD, delved into the major advances in genitourinary cancer treatment, including breakthroughs in immunotherapy, targeted therapies, and early detection that offer new hope for patients.
Read More
TKI and PD-L1 Therapy Combinations Show Long-Term Durability in Advanced RCC
January 17th 2024In this Q&A discussion, Hans Hammers, MD, PhD, explains the rationale for continued use of tyrosine kinase inhibitor and PD-L1 therapy combinations, like lenvatinib and pembrolizumab, for patients with advanced renal cell carcinoma.
Read More
Nadofaragene Firadenovec Continues to Demonstrate Durable Activity in NMIBC
January 17th 2024Three-year data showed durable clinical activity with nadofaragene firadenovec-vncg in patients with high-risk, BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors.
Read More
Current Standard-of-Care Treatment for Patients With BCG-Unresponsive High-Risk NMIBC
November 30th 2023BCG-unresponsive NMIBC treatment aims to eradicate disease or prolong disease-free intervals, with radical cystectomy as gold standard; newer options like pembrolizumab and gemcitabine/docetaxel provide improved alternatives, though logistic challenges remain.
Watch
NFBISI-18 Questionnaire Provides QOL Insights in Urothelial Carcinoma
November 13th 2023An analysis, based on data from the JAVELIN 100 Bladder trial, found the NCCN/FACT Bladder Symptom Index-18 for assessing quality-of-life in patients with advanced urothelial carcinoma to be reliable and valid.
Read More